Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 16/20 | 0.71 |
| ▸ | NTSR1 | P30989 | 16/20 | 0.71 |
| ▸ | SORT1 | Q99523 | 14/20 | 0.71 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496684 | 0.96 | NTSR2 (0.67) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31280899 | 0.91 | NTSR1 (0.74) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30623611 | 0.88 | NTSR1 (0.65) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30294171 | 0.87 | NTSR1 (0.64) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29361023 | 0.87 | NTSR1 (0.74) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29414469 | 0.87 | NTSR1 (0.62) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL29940473 | 0.86 | NTSR1 (0.64) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31411493 | 0.86 | NTSR1 (0.62) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL30361896 | 0.85 | NTSR1 (0.61) | NTSR2NTSR1SORT1OPRM1OPRD1 | |
| SCHEMBL31151633 | 0.85 | NTSR1 (0.61) | NTSR2NTSR1SORT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106981-A1 | IMMUNOCYTOKINES FOR HEART FAILURE PREVENTION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-3377103-B2 | FUNCTIONAL ANTIBODY FRAGMENT COMPLEMENTATION FOR A TWO-COMPONENTS SYSTEM FOR REDIRECTED KILLING OF UNWANTED CELLS | REVITOPE LTD (GB) | 2025-03-12 | — | — | EP | disclosed |
| CN-119139561-A | Phage composite hydrogel, preparation method thereof and application thereof in promoting alveolar bone repair | 浙江大学 | 2024-12-17 | — | — | CN | disclosed |
| US-20240228586-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | THE UNIVERSITY OF CHICAGO (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399415-A1 | Twin Immune Cell Engager | REVITOPE LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| US-11702482-B2 | Twin immune cell engager | REVITOPE LIMITED (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11590198-B2 | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2023-02-28 | — | — | US | disclosed |
| US-20220323600-A1 | TEAC AND ATTAC IMMUNOONCOLOGY COMPOSITIONS AND METHODS | REVITOPE LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| US-20220281936-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | THE UNIVERSITY OF CHICAGO (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220259386-A1 | SUPRAMOLECULAR HYDROGELS | TECHNISCHE UNIVERSITEIT EINDHOVEN (NL) | 2022-08-18 | — | — | US | disclosed |
| US-11369662-B2 | Methods of treating inflammation with monomeric CXCL12 peptide | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259386-A1 | SUPRAMOLECULAR HYDROGELS | UROD, FGB, UACA | NTSR2 4517/4885NTSR1 4032/4885SORT1 3633/4885 |
| US-20240228586-A1 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | ADAM8, COL14A1, COL2A1 | NTSR2 4026/4885NTSR1 3229/4885SORT1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.